03/09/23 8:30 AMNasdaq : BWV earningslow floatBlue Water Vaccines Reports Year 2022 Financial Results and Recent Business HighlightsBlue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), today announced its financial results for the fiscal year ended December 31, 2022 and provided an update on recent business developments and Company progress. Blue WaterRHEA-AIneutral
02/06/23 10:15 AMNasdaq : BWV managementlow floatBlue Water Vaccines Appoints Seasoned Commercial Operations Leader Frank Jaeger as Senior Vice President of Marketing and Business DevelopmentBlue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), today announced the appointment of Frank Jaeger, seasoned commercial operations and business development executive, as Senior Vice President of Marketing and BusinessRHEA-AIneutral
02/01/23 9:15 AMNasdaq : BWV partnershiplow floatBlue Water Vaccines Announces Partnership with AbVacc for Joint Development of Novel Monkeypox and Marburg Vaccine CandidatesBlue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), a biopharmaceutical company developing transformational vaccines to address significant global health challenges, today announced a collaboration with AbVacc, Inc.RHEA-AIneutral
01/17/23 8:30 AMNasdaq : BWV managementlow floatBlue Water Vaccines Announces Appointment of Seasoned Public Market and Private Equity Investment Leader Timothy Ramdeen to Board of DirectorsBlue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), a biopharmaceutical company developing transformational vaccines to address significant global health challenges, today announced the appointment of Timothy Ramdeen, seasonedRHEA-AIneutral
01/09/23 8:30 AMNasdaq : BWV conferenceslow floatBlue Water Vaccines to Present at Biotech Showcase 2023 During the 41st Annual J.P. Morgan Healthcare Conference Week in San FranciscoBlue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), a biopharmaceutical company developing transformational vaccines to address significant global health challenges, today announced that BWV management will present at theRHEA-AIneutral
12/12/22 8:30 AMNasdaq : BWV low floatBlue Water Vaccines Announces Institutional Research Coverage by Two Notable Healthcare-Focused Wall Street Banks, Receives “Buy” Rating From BothBlue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), a biopharmaceutical company developing transformational vaccines to address significant global health challenges, today announced its first analyst coverage since going publicRHEA-AIneutral
12/06/22 8:30 AMNasdaq : BWV low floatBlue Water Vaccines Organizes Key Opinion Leader Event to Discuss Unmet Need for Acute Otitis Media and Pneumonia Vaccine and Its Streptococcus pneumoniae Vaccine CandidateBlue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”) a biopharmaceutical company developing transformational vaccines to address significant global health challenges, today announced the Company will host an online Key OpinionRHEA-AIneutral
12/01/22 8:30 AMNasdaq : BWV conferenceslow floatBlue Water Vaccines to Present Update on Novel, Live Attenuated, Intranasally Delivered Streptococcus pneumoniae Vaccine to Prevent Acute Otitis Media, Pneumococcal Pneumonia, and Invasive Pneumococcal Disease at the World Vaccine & Immunotherapy Congress West Coast 2022Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), today announced that Ali Fattom, Ph.D., will present at the World Vaccine & Immunotherapy Congress West Coast 2022 in San Diego, California on Thursday, December 1, 2022. Dr.RHEA-AIneutral
11/10/22 8:47 AMNasdaq : BWV buybackearningslow floatBlue Water Vaccines Reports Third Quarter 2022 Financial Results and Recent Business Highlights; Announces 5 Million Share Repurchase ProgramClosed private placement in August 2022, with net proceeds of approximately $8.7 million Announced plans to evaluate efficacy of BWV-201 for protection against non-invasive pneumococcal pneumonia in children and adults Board of Directors authorized a 5 million share repurchase program in NovemberRHEA-AIneutral
11/08/22 8:30 AMNasdaq : BWV managementlow floatBlue Water Vaccines Announces Appointment of Vuk Jeremić, Previous Chair of the Council of Europe’s Committee of Ministers and Previous President of the United Nations General Assembly, to Its Board of DirectorsBlue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), a biopharmaceutical company developing transformational vaccines to address significant global health challenges, today announced the appointment of seasoned advisor andRHEA-AIneutral